310 related articles for article (PubMed ID: 27019026)
1. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.
Levy O; Brennen WN; Han E; Rosen DM; Musabeyezu J; Safaee H; Ranganath S; Ngai J; Heinelt M; Milton Y; Wang H; Bhagchandani SH; Joshi N; Bhowmick N; Denmeade SR; Isaacs JT; Karp JM
Biomaterials; 2016 Jun; 91():140-150. PubMed ID: 27019026
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H
Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Dhar S; Kolishetti N; Lippard SJ; Farokhzad OC
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1850-5. PubMed ID: 21233423
[TBL] [Abstract][Full Text] [Related]
6. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
7. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
9. Superior performance of co-cultured mesenchymal stem cells and hepatocytes in poly(lactic acid-glycolic acid) scaffolds for the treatment of acute liver failure.
Liu M; Yang J; Hu W; Zhang S; Wang Y
Biomed Mater; 2016 Feb; 11(1):015008. PubMed ID: 26836957
[TBL] [Abstract][Full Text] [Related]
10. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice.
Yang J; Xie SX; Huang Y; Ling M; Liu J; Ran Y; Wang Y; Thrasher JB; Berkland C; Li B
Nanomedicine (Lond); 2012 Sep; 7(9):1297-309. PubMed ID: 22583574
[TBL] [Abstract][Full Text] [Related]
11. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
12. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
13. Development of porous PLGA/PEI1.8k biodegradable microspheres for the delivery of mesenchymal stem cells (MSCs).
Lee YS; Lim KS; Oh JE; Yoon AR; Joo WS; Kim HS; Yun CO; Kim SW
J Control Release; 2015 May; 205():128-33. PubMed ID: 25575866
[TBL] [Abstract][Full Text] [Related]
14. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
Mukerjee A; Vishwanatha JK
Anticancer Res; 2009 Oct; 29(10):3867-75. PubMed ID: 19846921
[TBL] [Abstract][Full Text] [Related]
15. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy.
Li B; Zhang LJ; Zhang ZL; Long M; Ren JH; Lin F; Wang X; Wei JX; Dong K; Zhang HZ
Anticancer Drugs; 2011 Mar; 22(3):213-22. PubMed ID: 21150773
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy.
Zhao Y; Tang S; Guo J; Alahdal M; Cao S; Yang Z; Zhang F; Shen Y; Sun M; Mo R; Zong L; Jin L
Sci Rep; 2017 Mar; 7():44758. PubMed ID: 28303966
[TBL] [Abstract][Full Text] [Related]
17. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
18. PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Chen Z; Penet MF; Krishnamachary B; Banerjee SR; Pomper MG; Bhujwalla ZM
Biomaterials; 2016 Feb; 80():57-67. PubMed ID: 26706476
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
20. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice.
Abou-ElNaga A; Mutawa G; El-Sherbiny IM; Abd-ElGhaffar H; Allam AA; Ajarem J; Mousa SA
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]